STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Cell Biology and Cellular Functions Review Article

Anti Covid-19 Drugs Suggested by Computational Methods: A Review

  1. B. Reshika Department of Life Sciences, CHRIST University
  2. Samiksha Shivaji Bhor Department of Biotechnology, BioNome

Abstract

Background and aims: Long COVID refers to the persistence of illness in individuals who have survived from COVID-19 infection. This article reviews long covid and the use of in silico techniques in drug development for COVID-19. Results: Many COVID-19 survivors have long COVID, which has become a burden in daily life. Various attempts have been undertaken to relieve symptoms and manage it, but there is no cure as of yet. Healthy lifestyle practices and periodic health assessment could be of some help. Many plant phytochemicals, synthetic medicines, and other compounds show tremendous potential in computational analysis and should be studied further in the laboratory employing in vivo and in vitro approaches to understand their biochemistry in the human body. Conclusions: This review will assist investigators in analyzing long COVID and further exploring the given compounds in order to find a cure for COVID-19.

Keywords

References (90)

  1. WHO Coronavirus (COVID-19) Dashboard. (n.d.). Retrieved February 23, 2023, from https://covid19.who.int
  2. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021:n1648. doi:10.1136/bmj.n1648
  3. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(3):869-875. doi:10.1016/j.dsx.2021.04.007
  4. Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426. doi:10.1016/j.socscimed.2020.113426
  5. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases. 2021;53(10):737-754. doi:10.1080/23744235.2021.1924397
  6. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. eClinicalMedicine. 2022;53:101624. doi:10.1016/j.eclinm.2022.101624
  7. Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmunity Reviews. 2020;19(7):102573. doi:10.1016/j.autrev.2020.102573
  8. Positive RT-PCR Test Results in Patients Recovered From COVID-19 | Infectious Diseases | JAMA | JAMA Network. (n.d.). Retrieved February 23, 2023, from https://jamanetwork.com/journals/jama/fullarticle/2762452
  9. Ranganathan P, Sengar M, Chinnaswamy G, Agrawal G, Arumugham R, Bhatt R, et al. Impact of COVID-19 on cancer care in India: a cohort study. The Lancet Oncology. 2021;22(7):970-976. doi:10.1016/s1470-2045(21)00240-0
  10. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. Journal of the Royal Society of Medicine. 2021;114(9):428-442. doi:10.1177/01410768211032850
  11. Yadav M, Dhagat S, Eswari JS. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. European Journal of Pharmaceutical Sciences. 2020;155:105522. doi:10.1016/j.ejps.2020.105522
  12. Altay O, Mohammadi E, Lam S, Turkez H, Boren J, Nielsen J, et al. Current Status of COVID-19 Therapies and Drug Repositioning Applications. iScience. 2020;23(7):101303. doi:10.1016/j.isci.2020.101303
  13. Gupta Y, Savytskyi OV, Coban M, Venugopal A, Pleqi V, Weber CA, et al. Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Molecular Aspects of Medicine. 2023;91:101151. doi:10.1016/j.mam.2022.101151
  14. Murillo J, Villegas LM, Ulloa-Murillo LM, Rodríguez AR. Recent trends on omics and bioinformatics approaches to study SARS-CoV-2: A bibliometric analysis and mini-review. Computers in Biology and Medicine. 2021;128:104162. doi:10.1016/j.compbiomed.2020.104162
  15. Singh MB, Sharma R, Kumar D, Khanna P, Mansi, Khanna L, et al. An understanding of coronavirus and exploring the molecular dynamics simulations to find promising candidates against the Mpro of nCoV to combat the COVID-19: A systematic review. Journal of Infection and Public Health. 2022;15(11):1326-1349. doi:10.1016/j.jiph.2022.10.013
  16. Amparo TR, Seibert JB, Silveira BM, Costa FSF, Almeida TC, Braga SFP, et al. Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study. Phytochemistry Reviews. 2021;20(5):1013-1032. doi:10.1007/s11101-021-09754-4
  17. Choe J, Har Yong P, Xiang Ng Z. The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm. Chemistry & Biodiversity. 2022;19(11). doi:10.1002/cbdv.202200655
  18. Nguyen QV, Chong LC, Hor YY, Lew LC, Rather IA, Choi SB. Role of Probiotics in the Management of COVID-19: A Computational Perspective. Nutrients. 2022;14(2):274. doi:10.3390/nu14020274
  19. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017;3(4):651-657. doi:10.1016/j.trci.2017.10.005
  20. Clark DE. What has computer-aided molecular design ever done for drug discovery? Expert Opinion on Drug Discovery. 2006;1(2):103-110. doi:10.1517/17460441.1.2.103
  21. Kumar V, Chandra S, Siddiqi M. Recent Advances in the Development of Antiviral Agents Using Computer-aided Structure Based Approaches. Current Pharmaceutical Design. 2014;20(21):3488-3499. doi:10.2174/13816128113199990636
  22. Selvaraj GF, Piramanayagam S, Devadasan V, Hassan S, Krishnasamy K, Srinivasan S. Computational analysis of drug like candidates against Neuraminidase of Human Influenza A virus subtypes. Informatics in Medicine Unlocked. 2020;18:100284. doi:10.1016/j.imu.2019.100284
  23. Mallipeddi, P., Kumar, G., W. White, S., & R. Webb, T. (2014). Recent Advances in Computer-Aided Drug Design as Applied to Anti-Influenza Drug Discovery [Text]. Bentham Science Publishers.https://www.ingentaconnect.com/content/ben/ctmc/2014/00000014/00000016/art00 004
  24. Tahir ul Qamar M, Maryam A, Muneer I, Xing F, Ashfaq UA, Khan FA, et al. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. Scientific Reports. 2019;9(1). doi:10.1038/s41598-018-38450-1
  25. Jha N, Prashar D, Rashid M, Shafiq M, Khan R, Pruncu CI, et al. Deep Learning Approach for Discovery of In Silico Drugs for Combating COVID-19. Journal of Healthcare Engineering. 2021;2021:1-13. doi:10.1155/2021/6668985
  26. Ozdemir ES, Ranganathan SV, Nussinov R. How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned? Expert Opinion on Drug Discovery. 2022;17(10):1061-1065. doi:10.1080/17460441.2022.2128333
  27. Maghsoudi S, Taghavi Shahraki B, Rameh F, Nazarabi M, Fatahi Y, Akhavan O, et al. A review on computer‐aided chemogenomics and drug repositioning for rationalCOVID‐19 drug discovery. Chemical Biology & Drug Design. 2022;100(5):699-721. doi:10.1111/cbdd.14136
  28. Palit P, Mukhopadhyay A, Chattopadhyay D. Phyto‐pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID‐19, based on its promising immunomodulatory, anti‐coagulant and anti‐viral property. Phytotherapy Research. 2021;35(8):4246-4257. doi:10.1002/ptr.7084
  29. Shaik FB, Swarnalatha K, Mohan MC, Thomas A, Chikati R, Sandeep G, et al. Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment. Clinical Nutrition Open Science. 2022;42:62-72. doi:10.1016/j.nutos.2021.12.004
  30. Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. Phytomedicine. 2021;85:153286. doi:10.1016/j.phymed.2020.153286
  31. Hosseini M, Chen W, Xiao D, Wang C. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. Precision Clinical Medicine. 2021;4(1):1-16. doi:10.1093/pcmedi/pbab001
  32. Yosri N, Abd El-Wahed AA, Ghonaim R, Khattab OM, Sabry A, Ibrahim MAA, et al. Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2. Foods. 2021;10(8):1776. doi:10.3390/foods10081776
  33. Festa M, Sansone C, Brunet C, Crocetta F, Di Paola L, Lombardo M, et al. Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. International Journal of Molecular Sciences. 2020;21(21):8364. doi:10.3390/ijms21218364
  34. Youssef FS, Alshammari E, Ashour ML. Bioactive Alkaloids from Genus Aspergillus: Mechanistic Interpretation of Their Antimicrobial and Potential SARS-CoV-2 Inhibitory Activity Using Molecular Modelling. International Journal of Molecular Sciences. 2021;22(4):1866. doi:10.3390/ijms22041866
  35. Verkhivker G. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. International Journal of Molecular Sciences. 2022;23(6):2928. doi:10.3390/ijms23062928
  36. Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. Bioorganic Chemistry. 2021;106:104490. doi:10.1016/j.bioorg.2020.104490
  37. Unni S, Aouti S, Thiyagarajan S, Padmanabhan B. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. Journal of Biosciences. 2020;45(1). doi:10.1007/s12038-020-00102-w
  38. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.00827
  39. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: Will this be the way forward? BioScience Trends. 2020;14(2):159-160. doi:10.5582/bst.2020.03058
  40. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;35:101738. doi:10.1016/j.tmaid.2020.101738
  41. Coronavirus outbreak: ICMR recommends use of hydroxy-chloroquine for critical COVID-19 cases—BusinessToday. (n.d.). Retrieved February 25, 2023, from https://www.businesstoday.in/latest/economy-politics/story/coronavirus-outbreak-icmr-recommends-use-hydroxy-chloroquine-critical-covid-19-cases-252762-2020-03-23
  42. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
  43. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949
  44. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.105938
  45. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72-73. doi:10.5582/bst.2020.01047
  46. Ohishi T, Goto S, Monira P, Isemura M, Nakamura Y. Anti-inflammatory Action of Green Tea. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2016;15(2):74-90. doi:10.2174/1871523015666160915154443
  47. Kaihatsu K, Yamabe M, Ebara Y. Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters. Molecules. 2018;23(10):2475. doi:10.3390/molecules23102475
  48. Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors – an in silico docking and molecular dynamics simulation study. Journal of Biomolecular Structure and Dynamics. 2020;39(12):4362-4374. doi:10.1080/07391102.2020.1779818
  49. Jang M, Park R, Park YI, Cha YE, Yamamoto A, Lee JI, et al. EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro. Biochemical and Biophysical Research Communications. 2021;547:23-28. doi:10.1016/j.bbrc.2021.02.016
  50. Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di Paola R, Cuzzocrea S. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? International Journal of Molecular Sciences. 2020;21(14):5171. doi:10.3390/ijms21145171
  51. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409-412. doi:10.1126/science.abb3405
  52. Nguyen TTH, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW, et al. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology Letters. 2012;34(5):831-838. doi:10.1007/s10529-011-0845-8
  53. Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2021;71(1):222-225. doi:10.1136/gutjnl-2021-324090
  54. Xu, K., Cai, H., Shen, Y., Ni, Q., Chen, Y., et al. (2020). [Management of COVID-19: The Zhejiang experience]. Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences, 49(2), 147–157. https://doi.org/10.3785/j.issn.1008-9292.2020.02.02
  55. Yahfoufi N, Mallet J, Graham E, Matar C. Role of probiotics and prebiotics in immunomodulation. Current Opinion in Food Science. 2018;20:82-91. doi:10.1016/j.cofs.2018.04.006
  56. Plaza-Díaz J, Ruiz-Ojeda F, Vilchez-Padial L, Gil A. Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases. Nutrients. 2017;9(6):555. doi:10.3390/nu9060555
  57. Wang Y, Wu Y, Wang Y, Xu H, Mei X, Yu D, et al. Antioxidant Properties of Probiotic Bacteria. Nutrients. 2017;9(5):521. doi:10.3390/nu9050521
  58. Grant PT, Mackie AM. Drugs from the sea—fact or fantasy? Nature. 1977;267(5614):786-788. doi:10.1038/267786a0
  59. Lindequist U. Marine-Derived Pharmaceuticals - Challenges and Opportunities. Biomolecules & Therapeutics. 2016;24(6):561-571. doi:10.4062/biomolther.2016.181
  60. Malve H. Exploring the ocean for new drug developments: Marine pharmacology. Journal of Pharmacy And Bioallied Sciences. 2016;8(2):83. doi:10.4103/0975-7406.171700
  61. Isah T. Stress and defense responses in plant secondary metabolites production. Biological Research. 2019;52(1). doi:10.1186/s40659-019-0246-3
  62. El-Kashef DH, Youssef FS, Hartmann R, Knedel TO, Janiak C, Lin W, et al. Azaphilones from the Red Sea Fungus Aspergillus falconensis. Marine Drugs. 2020;18(4):204. doi:10.3390/md18040204
  63. Youssef FS, Ashour ML, Singab ANB, Wink M. A Comprehensive Review of Bioactive Peptides from Marine Fungi and Their Biological Significance. Marine Drugs. 2019;17(10):559. doi:10.3390/md17100559
  64. Zhang X, Li Z, Gao J. Chemistry and Biology of Secondary Metabolites from Aspergillus Genus. The Natural Products Journal. 2019;8(4):275-304. doi:10.2174/2210315508666180501154759
  65. Barnes CO, Jette CA, Abernathy ME, Dam KMA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682-687. doi:10.1038/s41586-020-2852-1
  66. Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020;182(4):828-842.e16. doi:10.1016/j.cell.2020.06.025
  67. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ESD, Fera D. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses. 2021;13(1):134. doi:10.3390/v13010134
  68. Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Trends in Immunology. 2020;41(11):1006-1022. doi:10.1016/j.it.2020.09.004
  69. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274-1278. doi:10.1126/science.abc2241
  70. Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, et al. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell. 2020;183(4):1013-1023.e13. doi:10.1016/j.cell.2020.09.035
  71. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014-1018. doi:10.1126/science.abd0831
  72. Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature Communications. 2021;12(1). doi:10.1038/s41467-020-20789-7
  73. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-655. doi:10.1126/science.abc6952
  74. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643-650. doi:10.1126/science.abc5902
  75. Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369(6510):1505-1509. doi:10.1126/science.abc5881
  76. Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):950-957. doi:10.1126/science.abe3354
  77. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w
  78. Hurlburt NK, Seydoux E, Wan YH, Edara VV, Stuart AB, Feng J, et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nature Communications. 2020;11(1). doi:10.1038/s41467-020-19231-9
  79. Asarnow D, Wang B, Lee WH, Hu Y, Huang CW, Faust B, et al. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. Cell. 2021;184(12):3192-3204.e16. doi:10.1016/j.cell.2021.04.033
  80. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182(5):1295-1310.e20. doi:10.1016/j.cell.2020.08.012
  81. Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850-854. doi:10.1126/science.abf9302
  82. Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597(7874):97-102. doi:10.1038/s41586-021-03807-6
  83. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host & Microbe. 2021;29(1):44-57.e9. doi:10.1016/j.chom.2020.11.007
  84. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host & Microbe. 2021;29(3):463-476.e6. doi:10.1016/j.chom.2021.02.003
  85. Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications. 2021;12(1). doi:10.1038/s41467-021-24435-8
  86. Chen F, Liu Z, Jiang F. Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Frontiers in Immunology. 2021;12. doi:10.3389/fimmu.2021.690742
  87. Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Frontiers in Immunology. 2021;12. doi:10.3389/fimmu.2021.647934
  88. Aria H, Mahmoodi F, Ghaheh HS, Faranak mavandadnejad, Zare H, Heiat M, et al. Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review. Analytical Biochemistry. 2022;640:114546. doi:10.1016/j.ab.2022.114546
  89. Sasisekharan R. Preparing for the Future — Nanobodies for Covid-19? New England Journal of Medicine. 2021;384(16):1568-1571. doi:10.1056/nejmcibr2101205
  90. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Research. 2022;51(D1):D1373-D1380. doi:10.1093/nar/gkac956